In summary, our research affirms that p53/PD-L1 co-expression in patients with DLBCL displays a significant adverse prognostic influence, and that the clinical outcome of this cohort cannot be necessarily improved by incorporating Rituximab into chemotherapy treatment. The gene discussed is CD274; the disease is diffuse large B-cell lymphoma.